AstraZeneca Pharma India Ltd.

NSE: ASTRAZEN | BSE: 506820

AstraZeneca Pharma Live Share Price Today, Share Analysis and Chart

aboutAstraZeneca Pharma India Limited is a global, science-led biopharmaceutical company and a subsidiary of the AstraZeneca Group. It focuses on the discovery, development, and commercialization of prescription medicines in key therapeutic areas includin... Read More

US FDA Inspections

65.50(1.04%)

35.38% Fall from 52W High

6,964

NSE+BSE Volume

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Board Meeting

The next board meeting for AstraZeneca Pharma is on 05 Nov 2026 for the purpose of Quarterly Results See details

Durability score

- / 100

Valuation Score

- / 100

Momentum Score

36.0 / 100

Expensive PerformerThese stocks have medium quality and momentum.Their expensive valuations suggest cautionView Similar Embed DVM

Analyst Price Target

No estimates available

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

Medium rank

10Positive12Negative

45.5%Pass in checklist

045

100

Check P/E Buy Sell Zone

Buy Zone

28.0 % into P/E buy sell zone

% time spent below current P/E

020406080100

Strong upside potential

Gains already realized

AstraZeneca Pharma Stock Price Analysis

Day Price Range 1.0% 1 Day return	6364.5 (LTP) 6,240.56,380 LowHigh
Week Price Range 6.3% 1 Week return	6364.5 (LTP) 5,8886,400 LowHigh
Month Price Range 2.9% 1 Month return	6364.5 (LTP) 5,6406,400 LowHigh
52 Week Price Range -33.4% 1 Year return	6364.5 (LTP) 5,6409,849.5 LowHigh

View full Price History/Seasonality

Competitors/Peers

Revenue Mix

Quarterly

Annual

Balance Sheet

Ratios

Cash Flow

Documents

AstraZeneca Pharma quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

Nested row level

Base Level

Export

POSITIVE
Quarterly Revenue AstraZeneca Pharma Jun-2026 Quarterly Revenue is Rs 692 Cr which is growth of 28.7% YoY.
NEGATIVE
Quarterly Net Profit AstraZeneca Pharma Jun-2026 Quarterly Net Profit is Rs 38 Cr which is growth of -32.1% YoY.

AstraZeneca Pharma India Ltd., Quarterly, standalone, All financials are in INR Cr and price data in INR
Indicator	Jun '26	Mar '26	Dec '25	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24	Mar '24	Dec '23	Sep '23	Jun '23
TOTAL_SR_Q Total Rev. ⌄	692	584.6	616.7	565.3	537.6	496.6	448.3	416.2	395.9	391.9	315.5	319.4	303.6
SR_Q Operating Rev.	682.8	578.6	611.6	559.1	526.3	480.5	440.3	408	387.5	383.2	305.8	311.1	295.5
OI_Q Other Income	9.2	6	5.1	6.2	11.2	16.2	8	8.2	8.4	8.7	9.7	8.4	8.1
OEXPNS_Q Operating Exp.	633.9	517.7	566.7	483.9	445.2	394.1	363.5	355.5	349.4	333.8	290.7	258.3	228.2
OEXPNS_Q Operating Exp.	633.9	517.7	566.7	483.9	445.2	394.1	363.5	355.5	349.4	333.8	290.7	258.3	228.2
OP_Q Operating Profit	48.9	60.9	44.8	75.2	81.1	86.4	77	52.5	38.1	49.4	15.1	52.8	67.3
OPMPCT_Q Operating Profit Margin %	7.17%	10.53%	7.33%	13.45%	15.41%	17.98%	17.49%	12.88%	9.83%	12.89%	4.92%	16.96%	22.76%
DEP_Q Depr.	5.2	5.6	3.8	2.6	16.6	17.7	9.1	9.3	3.9	3.8	3.7	3.7	3.8
INT_Q Interest	2	2	1.1	0.7	0.7	0.7	0.3	0.3	0.1	-0.1	0.6	0.5	0.2
PBT_Q Profit Before Tax	50.8	58.1	46.5	72.8	74.7	78.5	42	51	-15.2	54.4	20.4	73.4	71.4
TAX_Q Tax	12.8	13.3	14	18.6	18.9	20.2	11.2	12.6	-3.4	14.9	4.6	21	17.5
NP_Q Net Profit	37.9	44.9	32.6	54.2	55.8	58.3	30.9	38.4	-11.8	39.5	15.8	52.4	53.9
EPS_adj_Q EPS Adj. latest	15.2	18	13	21.7	22.3	23.3	12.3	15.4	-4.7	15.8	6.3	21	21.5
NP_TTM Net profit TTM	169.6	187.5	200.9	199.2	183.4	115.7	97	81.9	95.9	161.5	139.3	152.8	133
EPS_TTM Basic EPS TTM	67.9	75	80.4	79.7	73.3	46.3	38.8	32.8	38.3	64.6	55.7	61.1	53.2
results_pdf Results PDF
result_notes Result Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

VIEW ALL TABLE IN FINANCIAL PAGE

AstraZeneca Pharma Technical Analysis

AstraZeneca Pharma EMA & SMA

Bullish+2

5 bullish, 3 bearish

Bullish5

Bearish3

5 Day	6236.6
10 Day	6157.7
12 Day	6145.4
20 Day	6167.2

26 Day	6226.1
50 Day	6548.6
100 Day	7092.2
200 Day	7635.4

AstraZeneca Pharma Delivery And Volume

Daily Avg. Delivery Volume %

30 Oct, 202656.8%

Week49.3%

Month59.4%

AstraZeneca Pharma Active Candlesticks

Short Line Uptrend

Legend

Positive IndicatorNeutral IndicatorNegative Indicator

AstraZeneca Pharma Resistance and Support

6328.33

Pivot

First Resistance	6416.2
Second Resistance	6467.8
Third Resistance	6555.7

First Support	6276.7
Second Support	6188.8
Third Support	6137.2

Day RSI	56.6
Day MACD	-80.7
Day MFI	68
Day MACD Signal Line	-167.2

AstraZeneca Pharma Beta

1 Month	0.6
1 Year	0.5

3 Month	0.8
3 Year	0.6

AstraZeneca Pharma Price Change Analysis

↑2.9%

Over 1 Month

LowHigh

56406400

↓-21.4%

Over 3 Months

LowHigh

56408510

↓-22.5%

Over 6 Months

LowHigh

56409150

↓-33.4%

Over 1 Year

LowHigh

56409849.5

AstraZeneca Pharma Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026

Name	Category	Shares	Shares %
Astrazeneca Pharmaceuticals Ab	Promoter	18,750,000	75 %
Tejas Bhalchandra Trivedi	Public	574,081	2.3 %
Nippon Life India Trustee Ltd-A/C Nippon India Small Cap Fund(Various Schemes)	Dii	724,443	2.9 %

HISTORICAL PROMOTER HOLDING

Promoters holding remains unchanged at 75.00% in Sep 2026 qtr

HISTORICAL FII HOLDING

FII/FPI have decreased holdings from 2.68% to 2.64% in Sep 2026 qtr

HISTORICAL MF HOLDING

Mutual Funds have increased holdings from 6.01% to 7.01% in Sep 2026 qtr.

All Shareholding details

AstraZeneca Pharma Deals - Insider, Bulk, Block and SAST

Client Name	Deal Type	Action	Date	Avg. Price	Quantity	Exchange
GRAVITON RESEARCH CAPITAL LLP	Bulk	Sell	07 Oct 2024	7887.16	125,166	NSE
GRAVITON RESEARCH CAPITAL LLP	Bulk	Purchase	07 Oct 2024	7884.41	125,166	NSE
GRAVITON RESEARCH CAPITAL LLP	Bulk	Sell	30 Sep 2024	7804.96	127,119	NSE
GRAVITON RESEARCH CAPITAL LLP	Bulk	Purchase	30 Sep 2024	7802	127,119	NSE
GRAVITON RESEARCH CAPITAL LLP	Bulk	Sell	24 Sep 2024	7506.36	131,308	NSE
GRAVITON RESEARCH CAPITAL LLP	Bulk	Purchase	24 Sep 2024	7499.17	131,308	NSE
ISHARES INDIA SC MAURITIUS COMPANY	Block	Sell	19 Sep 2022	3152.55	6,542	BSE
ISHARES CORE EMERGING MARKETS MAURITIUS CO	Block	Sell	19 Sep 2022	3152.55	74,097	BSE
ISHARES CORE MSCI EMERGING MARKETS ETF	Block	Purchase	19 Sep 2022	3152.55	74,097	BSE
ISHARES MSCI INDIA SMALL-CAP ETF	Block	Purchase	19 Sep 2022	3152.55	6,542	BSE

All deals

All insider trades

AstraZeneca Pharma Corporate Actions

AstraZeneca Pharma Dividend history and yield

AstraZeneca Pharma dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track AstraZeneca Pharma dividend yield over time.

#Ex-Date	Dividend Amount	Dividend Type	Record Date	Instrument Type
131 Jul 2026	36	FINAL	31 Jul 2026	Equity Share
218 Jul 2025	32	FINAL	18 Jul 2025	Equity Share
305 Jul 2024	24	FINAL	05 Jul 2024	Equity Share
414 Jul 2023	16	FINAL	14 Jul 2023	Equity Share
507 Jul 2022	8	FINAL	08 Jul 2022	Equity Share

AstraZeneca Pharma Board Meetings

AstraZeneca Pharma past and upcoming board meetings.

#Ex-Date	Purpose	Notes
105 Nov 2026	Quarterly Results	-
210 Aug 2026	Quarterly Results	-
326 May 2026	Audited Results & Final Dividend	-
411 Feb 2026	Quarterly Results	-
507 Nov 2025	Quarterly Results	-

AstraZeneca Pharma Stock Split

AstraZeneca Pharma stock split details, including announcement, record, and ex-split dates, along with the split ratios

#Ex-Date	Old FV	New FV	Record Date
115 Jun 2006	10	2	22 Jun 2006

All Corporate Actions

AstraZeneca Pharma Research Reports

AstraZeneca Pharma research reports with share price targets, and buy/hold/sell recommendations from top brokers.

# Date	Broker Name	Target	Price When Recommended	Type	Upside	Change Since Recommendation	Links
107 Nov 2017	Rudra Shares and Stock Brokers Ltd	1420	1164	Buy	21.99%	446.78%	pdf

All Reports of AstraZeneca

AstraZeneca Pharma Corporate Filings

AstraZeneca Pharma BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

Date	Announcement Title	Details	Links
30 Oct 2026	AstraZeneca Pharma India Ltd - 506820 - Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Thursday, November 5, 2026	Astrazeneca Pharma India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve the Un-audited Financial Results of the Company for the quarter and half year ended September 30, 2026. We also confirm that the 'Trading Window' remains closed for all Designated Persons, from September 16, 2026 to November 7, 2026 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015.	PDF
26 Oct 2026	AstraZeneca Pharma India Ltd - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018	Please find the enclosed intimation of the Company as per the captioned subject for your reference.	PDF
16 Oct 2026	AstraZeneca Pharma India Ltd - 506820 - Announcement under Regulation 30 (LODR)-Press Release / Media Release	Please find the enclosed Press Release as per the captioned subject for your reference.	PDF
16 Oct 2026	AstraZeneca Pharma India Ltd - 506820 - Shareholder Meeting / Postal Ballot-Outcome of Postal Ballot	Please find the enclosed letter of the Company as per the captioned subject for your reference.	PDF
16 Oct 2026	AstraZeneca Pharma India Ltd - 506820 - Announcement under Regulation 30 (LODR)-Credit Rating	Please find the enclosed intimation of the Company as per the captioned subject for your reference.	PDF

VIEW ALL

AstraZeneca Pharma DocumentsAsk MarketMind AI

AstraZeneca Pharma Annual Reports

AstraZeneca Pharma financials, including annual results, balance sheets, and cash flow statements.

Date	Report Title	Links
2026	Annual Report Mar-2026	Link
2025	Annual Report Mar-2025	Link
2024	Annual Report Mar-2024	Link
2023	Annual Report Mar-2023	Link
2022	Annual Report Mar-2022	Link

AstraZeneca Pharma - Company Profile

AstraZeneca Pharma Management Structure

AstraZeneca Pharma management structure with salaries, total experience, and qualifications.

NAME	DESIGNATION	GROSS REMUNERATION ₹(LAC)	AS OF
Bhavana Agrawal	Executive Director,Whole Time Director,Chief Financial Officer	-	Mar 26
Ms. Amarpreet Kaur Ahuja	Director(Human Resources)	-	Mar 26
Dr. Sandeep Arora	Director(Medical Affairs)	-	Mar 26
Ms. Amita Bhave	Director(Regulatory Affairs)	-	Mar 26
Mr. Ayush Kumar Agarwal	Business Unit Head(Biopharmaceutical Development)	-	Mar 26
Ms. Shikha Mirchandani Chatrath	Director(Commercial Excellence,BD.,Strategy)	-	Mar 26
Mr. Vinay Sharma	Business Unit Head(Rare Disease)	-	Mar 26
Mr. Venkat Natarajan	Lead.(Market Access)	-	Mar 26
Mr. Harish Dash	Senior Director(Commercial,IT,Digital)	-	Mar 26
Mr. Srikanth B.S.	Lead.(India Operations)	-	Mar 26
Tanya Sanish	Company Secretary,Compliance Officer	-	Mar 26
Ms. Aditi Dayarus Mehta	Director(Oncology)	-	Mar 26
Mr. Nitin Bindal	Director(Institutional Business,Channels.)	-	Mar 26
Ms. Sandhya Amanna Tejaswini	Director(Legal.)	-	Mar 26

AstraZeneca Pharma Board of Directors

AstraZeneca Pharma Board of directors with salaries, total experience, and qualifications.

NAME	POSITION	GROSS REMUNERATION ₹(LAC)	AS OF
Praveen Rao Akkinepally	Managing Director / Business Unit Head	389.17	Mar 26
Bhavana Agrawal	Executive Director / Whole Time Director / CFO	256.31	Mar 26
Revathy Ashok	Independent Non Exe. Director	14	Mar 26
MONICA WIDHANI	Independent Non Exe. Director	14	Mar 26
Shilpa Divekar Nirula	Chairman & Independent Directo	11	Mar 26
Hooi Bien Chuah	Non Executive Director	-	Mar 26
Tanya Sanish	Company Sec. & Compli. Officer	-	Mar 26

Website: www.astrazeneca.in

About the company - Business Profile

AstraZeneca Pharma India Limited is a global, science-led biopharmaceutical company and a subsidiary of the AstraZeneca Group. It focuses on the discovery, development, and commercialization of prescription medicines in key therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism (CVRM), Respiratory & Immunology, and Rare Diseases. The company serves as a critical link in providing innovative global therapies to the Indian market, leveraging its parent company's extensive research and development pipeline.

Key Points

Key Facts:
- Founded: 1979 (Incorporated).
- Headquarters: Bengaluru, Karnataka.
- Parent Company: AstraZeneca PLC, UK (holds a 75% stake through AstraZeneca AB, Sweden).
- Stock Listing: Listed on BSE and National Stock Exchange (NSE).
- Primary Offerings: Innovative medicines for cancer, chronic kidney disease, type-2 diabetes, and asthma.
Operations and Resources:
- Facilities: Operates a manufacturing facility at Yelahanka, Bengaluru, which is engaged in the formulation of pharmaceutical products.
- Integration: Closely integrated with AstraZeneca’s global supply chain and clinical research operations. The Bengaluru site also houses a Global Technology Centre (GTC) providing IT and technical support to the global group.
Market and Significance:
- Industries Served: Healthcare and Pharmaceuticals.
- Strategic Importance: Acts as a vehicle for the launch of innovative global molecules in India. It is a major player in the Indian Oncology and CVRM segments.
Business Model and Strengths:
- Model: Focuses on a Growth Through Innovation strategy. It imports, manufactures, and markets high-end innovative medicines. It excels in bringing first-in-class or best-in-class therapies to patients with high unmet medical needs.
- Revenue Breakdown (FY 2024-25):
  - Total Revenue from Operations: ₹1,312 crore (approximate, based on projected trends from the 2024-25 reporting cycle).
  - Geographical: Primary revenue is generated from domestic sales within India, with minor exports to group companies.
Key Products and Advancements:
- Oncology: Key brands include Tagrisso (Lung Cancer), Lynparza (Ovarian/Breast Cancer), and Imfinzi.
- CVRM: Notable products include Forxiga (Diabetes and Heart Failure) and Brilinta (Acute Coronary Syndrome).
- Respiratory: Includes Symbicort and Fasenra.
- Technology: Implementation of patient-centric digital tools and diagnostic partnerships to improve early disease detection.
Partnerships and Contracts:
- Collaborates with local diagnostic labs and hospitals for genomic testing and early screening programs in oncology.
- Partners with various state governments for health awareness and screening initiatives (e.g., 'Ganga' program for kidney health).
Employees and Sustainability:
- Employee Count: Approximately 1,200+ employees.
- Sustainability: Committed to the Ambition Zero Carbon program, aiming to reduce Scope 1 and 2 emissions significantly. The Yelahanka factory has transitioned to using renewable energy sources for a significant portion of its requirements.
Strategic Initiatives and Outlook:
- BOLD Ambition: Focuses on accelerating the launch of 15+ new molecular entities (NMEs) globally by 2030, many of which are slated for the Indian market.
- Future Outlook: The company is expanding its portfolio in Rare Diseases following the global integration of Alexion. It aims to broaden market access through price-volume agreements and government partnerships.

References

AstraZeneca Pharma FAQ

AstraZeneca Pharma today is trading in the green, up by 1.04% at ₹6,364.5.

AstraZeneca Pharma is currently trading up 1.04% on an intraday basis. In the past week the stock rose 6.28%. Stock has been down 21.43% in the past quarter and fell 33.39% in the past year. You can view this in the share price history/seasonality section.

AstraZeneca Pharma is listed on NSE with the ticker ASTRAZEN and on BSE as 506820. It's currently trading on NSE at a share price of ₹6,364.5 and on BSE with a share price of ₹6,383.2.

The market cap of AstraZeneca Pharma is ₹15,911.25 Cr. as of Oct 30, 2026.

AstraZeneca Pharma announced a FINAL dividend of 1800% which equals ₹36 in Jul 31, 2026.The last three ex-dates for AstraZeneca Pharma were Jul 18, 2025, Jul 05, 2024 and Jul 14, 2023. To view the full dividend history of AstraZeneca Pharma click here.

AstraZeneca Pharma has never issued bonus shares, but it has issued 1 stock split since its BSE/NSE listing. The latest announcement for AstraZeneca Pharma stock split was on Jun 15, 2006 at a ratio of 10:2.

AstraZeneca Pharma reported ₹692.02 Cr. in revenue, ₹37.93 Cr. in net profit, and ₹57.93 Cr. in EBITD as of Aug 10, 2026 for Q1 FY26-27.

There are no analyst predictions for stock price target for AstraZeneca Pharma.

The PE ratio of AstraZeneca Pharma is 93.81 as of Oct 30, 2026.

The PB ratio of AstraZeneca Pharma is 17.47 as of Oct 30, 2026.

There are no analyst reports for AstraZeneca Pharma.

You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.

Key Metrics
DVM
Price Chart
Forecaster
Financials
Technicals
Shareholding
Deals
Documents
Corporate actions
Company Profile

AstraZeneca Pharma Live Share Price Today, Share Analysis and Chart

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

AstraZeneca Pharma Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

AstraZeneca Pharma - Quarterly

AstraZeneca Pharma quarterly results: revenue, profit, and P&L – 13 quarter history

Quarterly Revenue AstraZeneca Pharma Jun-2026 Quarterly Revenue is Rs 692 Cr which is growth of 28.7% YoY.

Quarterly Net Profit AstraZeneca Pharma Jun-2026 Quarterly Net Profit is Rs 38 Cr which is growth of -32.1% YoY.

AstraZeneca Pharma Technical Analysis

AstraZeneca Pharma EMA & SMA

AstraZeneca Pharma Delivery And Volume

AstraZeneca Pharma Active Candlesticks

AstraZeneca Pharma Resistance and Support

AstraZeneca Pharma Beta

AstraZeneca Pharma Price Change Analysis

AstraZeneca Pharma Shareholding Pattern/ Ownership

Shareholding Summary

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

AstraZeneca Pharma Deals - Insider, Bulk, Block and SAST

Bulk Block Deals

Insider Trading & SAST

AstraZeneca Pharma Corporate Actions

AstraZeneca Pharma Dividend history and yield

AstraZeneca Pharma dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track AstraZeneca Pharma dividend yield over time.

AstraZeneca Pharma Board Meetings

AstraZeneca Pharma past and upcoming board meetings.

AstraZeneca Pharma Stock Split

AstraZeneca Pharma stock split details, including announcement, record, and ex-split dates, along with the split ratios

AstraZeneca Pharma Research Reports

AstraZeneca Pharma research reports with share price targets, and buy/hold/sell recommendations from top brokers.

AstraZeneca Pharma Corporate Filings

AstraZeneca Pharma BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

AstraZeneca Pharma DocumentsAsk MarketMind AI

AstraZeneca Pharma Annual Reports

AstraZeneca Pharma financials, including annual results, balance sheets, and cash flow statements.

AstraZeneca Pharma - Company Profile

AstraZeneca Pharma Management Structure

AstraZeneca Pharma management structure with salaries, total experience, and qualifications.

AstraZeneca Pharma Board of Directors

AstraZeneca Pharma Board of directors with salaries, total experience, and qualifications.

About the company - Business Profile

Key Points

AstraZeneca Pharma FAQ

How is AstraZeneca Pharma today?

AstraZeneca Pharma today is trading in the green, up by 1.04% at ₹6,364.5.

How has AstraZeneca Pharma performed historically?

AstraZeneca Pharma is currently trading up 1.04% on an intraday basis. In the past week the stock rose 6.28%. Stock has been down 21.43% in the past quarter and fell 33.39% in the past year. You can view this in the share price history/seasonality section.

What is the current share price of AstraZeneca Pharma on NSE and BSE exchanges?

AstraZeneca Pharma is listed on NSE with the ticker ASTRAZEN and on BSE as 506820. It's currently trading on NSE at a share price of ₹6,364.5 and on BSE with a share price of ₹6,383.2.

What is the market cap of AstraZeneca Pharma?

The market cap of AstraZeneca Pharma is ₹15,911.25 Cr. as of Oct 30, 2026.

When did AstraZeneca Pharma last pay a dividend, and what has its dividend history been?

AstraZeneca Pharma announced a FINAL dividend of 1800% which equals ₹36 in Jul 31, 2026.The last three ex-dates for AstraZeneca Pharma were Jul 18, 2025, Jul 05, 2024 and Jul 14, 2023. To view the full dividend history of AstraZeneca Pharma click here.

Has AstraZeneca Pharma issued any bonus shares or share splits recently?

AstraZeneca Pharma has never issued bonus shares, but it has issued 1 stock split since its BSE/NSE listing. The latest announcement for AstraZeneca Pharma stock split was on Jun 15, 2006 at a ratio of 10:2.

What do the financial statements and annual reports of AstraZeneca Pharma Indicate?

AstraZeneca Pharma reported ₹692.02 Cr. in revenue, ₹37.93 Cr. in net profit, and ₹57.93 Cr. in EBITD as of Aug 10, 2026 for Q1 FY26-27.

What is the target share price of AstraZeneca Pharma according to analyst predictions in FY26-27?

There are no analyst predictions for stock price target for AstraZeneca Pharma.

What is the PE Ratio of AstraZeneca Pharma?

The PE ratio of AstraZeneca Pharma is 93.81 as of Oct 30, 2026.

What is the PB Ratio of AstraZeneca Pharma?

The PB ratio of AstraZeneca Pharma is 17.47 as of Oct 30, 2026.

Where can I check the latest Research Reports about AstraZeneca Pharma?

There are no analyst reports for AstraZeneca Pharma.

How can I be notified of real time alerts about AstraZeneca Pharma stock?

You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.